TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06205797
Drug: HU-045
Approvals — FDA: no, EMA: no, PMDA: no
Description: HU-045 is a medicine that is injected into muscles and used to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults for a short period of time (temporary). It should be reconstituted with sterile, preservative-free 0.9% saline before use.~White powder~Other Names:~IncobotulinumtoxinA
Study: NCT06205797
Drug: Xeomin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xeomin® is a prescription medicine that is injected into muscles and used to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults for a short period of time (temporary). It should be reconstituted with sterile, preservative-free 0.9% saline before use.~Other Names:~IncobotulinumtoxinA
Study: NCT06112678
Drug: CKD-828, D097, D337
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD, PO
Study: NCT05702190
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administration of placebo as 2x5 drops on day 1, 3x10 drops on days 2-8, and 1x10 drops on day 9 in each study period.
Study: NCT05588297
Drug: CapOx(Capecitabine+ Oxaliplatin)
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: CapOx: Capecitabine is given orally at 1500mg / m² twice a day from day1-14 every 3 weeks for 4 cycles and Oxaliplatin is given by intravenous infusion at 200mg / m2 on Day 1 every 3 weeks for 4 cycles
Study: NCT04937309
Drug: usual medical treatment
Normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard anti emetic treatments to prevent emesis due to chemotherapy
Study: NCT06062069
Drug: : CT-868 Pen Injector, Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo pen injector is identical and contains the same ingredients except for CT-868.
Study: NCT04854096
Drug: Best Available Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Comparator
Study: NCT06362265
Drug: LY3209590
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT05776927
Drug: Rescue Medication
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol 100μg / Albuterol 90μg
Study: NCT05351697
Drug: BR105 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2mg/kg, 1mg/kg, 3mg/kg, 10mg/kg, 20mg/kg, 30mg/kg, 40mg/kg respectively
Study: NCT04375800
Drug: 2 NRTIs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive 2 NRTIs per local label by mouth for 96 weeks as background therapy.
Study: NCT05501470
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06029595
Drug: Experimental: CHF6001 3200 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 μg/actuation - 2 inhalations of CHF6001 800 μg twice daily (BID) total daily dose 3200 μg
Study: NCT06029595
Drug: Placebo Comparator: CHF6001 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 inhalations of CHF6001 matching placebo BID
Study: NCT05456854
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of placebo \*16 hr
Study: NCT05431426
Drug: CH6001
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF6001 will be administered using the NEXThaler® DPI device
Study: NCT04999020
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dosing will consist of a loading dose followed by maintenance doses administered q8w. The maintenance dosing will be initiated 2 weeks after the loading dose is administered.
Study: NCT05363839
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered orally via a capsule.
Study: NCT04748705
Drug: Placebo BID Tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will take 1 tablet twice daily, each morning and evening, of randomly assigned study drug orally starting on Day 1 through study duration.
Study: NCT05387785
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered placebo capsule
Study: NCT05294341
Drug: Norethindrone 0.35 MG
Normalized name: norethindrone 0.35 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: As specified in arm design
Study: NCT04702997
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule containing an inert placebo
Study: NCT06062953
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-9 mg flexible dosing before bed time
Study: NCT06062953
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-3 capsules flexible dosing before bed time
Study: NCT04675931
Drug: KAE609
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of Intravenous Cipargamin will be evaluated in the initial phase of the study (Cohorts 1-2).~These doses will cover a wider exposure range and facilitate the selection of an appropriate dose for later Cohorts 3-5.
Study: NCT06181513
Drug: Probiotic Blend Capsule
Normalized name: Probiotic Blend Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 million CFU (Lactobacillus paracasei, Lactobacillus plantarum, Lactobacillus rhamnosus, Lactobacillus helveticus, Bifidobacterium breve)
Study: NCT05957822
Drug: TXA
Normalized name: TXA>2<
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tranexamic acid injection 8-10mg/kg
Study: NCT05476770
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Give intrathecally:~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients ≥9 years of age
Study: NCT05476770
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given intrathecally.~AML Patients:~Age 1-1.99 - 16 mg Age 2-2.99 - 20 mg Age ≥3 years of age - 24 mg~AML Patients:~Age 1-1.99 - 8 mg Age 2-2.99 - 10 mg Age 3-8.99 - 12 mg Age ≥9 years of age - 15 mg
Study: NCT05525780
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A matched volume of placebo product will be administered to each subject in each cohort.
Study: NCT05525780
Drug: Oral cohort
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of Aricept tablet
Study: NCT05978089
Drug: Yangxinshi tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment group was given Yangxinshi tablets (3 tablets/time and 3 times/day). The treatment period was 24 weeks.
Study: NCT05978089
Drug: Yangxinshi tablet simulants
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control group was given Yangxinshi tablet simulants (3 tablets/time and 3 times/day).The treatment period was 24 weeks.
Study: NCT05718492
Drug: FOLFOX (oxaliplatin , leucovorin , fluorouracil , and fluorouracil )
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Hepatic artery infusion chemotherapy. The FOLFOX (oxaliplatin 130 mg/m2, leucovorin 200 mg/m2, fluorouracil 400 mg/m2, and fluorouracil 2,400 mg/m2) regimen was sequentially infused through the catheter every cycle (3 weeks).
Study: NCT05772234
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fluid infusion with normal saline (maximum of 1.5mL/kg per h or 3L per 24h).
Study: NCT06421376
Drug: Cardonilizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two cycles of Inductive therapy： nab-paclitaxel 250mg/ m2+cisplatin 75mg/ m2+Cardonilizumab 10mg/kg，ivgtt，3 weeks per cycle for 2 cycles
Study: NCT05209256
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the alflutinib group received alflutinib (80 mg daily) until disease progression, unacceptable toxicity, or death.
Study: NCT04880031
Drug: Efimosfermin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efimosfermin will be administered by subcutaneous injection
Study: NCT06092684
Drug: Ketanest®S
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dosage for anesthesia induction period was 0.5mg/kg, and the dosage for anesthesia maintenance period was 0.5mg/kg/h.
Study: NCT04880031
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered by subcutaneous injection
Study: NCT05751720
Drug: GIP/GLP-1a
Approvals — FDA: no, EMA: no, PMDA: no
Description: The group will receive GLP-1 analogues (subcutaneous Tirzepatide). The dose of Tirzepatide is 0.25 mg once weekly for 4 weeks then 0.5 mg once weekly.
Study: NCT06106308
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI (irinotecan + fluorouracil \[5-FU\] + leucovorin) as intravenous (IV) infusion
Study: NCT06106308
Drug: FOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX (leucovorin + fluorouracil \[5-FU\] + oxaliplatin) as intravenous (IV) infusion
Study: NCT05630235
Drug: CBD/CBD-A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be administered a one-time dose of 217.7 mg of CBD/CBD-A orally.
Study: NCT06156566
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 capsules, twice daily, 14 days.
Study: NCT06719557
Drug: MK-1084
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT06719557
Drug: Phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral capsule (extended)
Study: NCT06720324
Drug: Fludarabine + Cyclophosphamide + CD7-specific CAR-T Cells
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fludarabine 30 mg/kg on day -5, -4, and -3; cyclophosphamide 300 mg/kg on day -5, -4, and -3; CD7-specific CAR-T Cells on day 0.
Study: NCT05642026
Drug: Non steroidal anti-inflammatory drug and opioids
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this group receive nonsteroidal and opioid pain medications (intravenous/oral inpatient and oral outpatient) per standard of care.
Study: NCT04636801
Drug: Experimental: CHF6001 1600µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF6001 400µg, 2 inhalations bid (total daily dose of 1600µg).
Study: NCT04636801
Drug: Experimental: CHF6001 3200µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF6001 800µg, 2 inhalations bid (total daily dose of 3200µg).
Study: NCT04636801
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF6001 matching placebo, 2 inhalations bid.
Study: NCT06066710
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be given on the same schedule as the propranolol regime.
Study: NCT05299099
Drug: IN-C006 inj.
Approvals — FDA: no, EMA: no, PMDA: no
Description: IN-C006 will be injected continuously for 3 days.
Study: NCT05299099
Drug: RCN301
Approvals — FDA: no, EMA: no, PMDA: no
Description: RCN301 will be injected continuously for 3 days.
Study: NCT05872958
Drug: AZD3152
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD3152 will be administered via IM injection or IV infusion, as per the assigned arms.
Study: NCT05335811
Drug: 4-[18F]Fluoro-1-Naphthol
Approvals — FDA: no, EMA: no, PMDA: no
Description: By vein (IV)
Study: NCT05667740
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline
Study: NCT05884671
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will receive placebo during one of the sessions.
Study: NCT04967092
Drug: Modified Xiao-Feng Powder + Antiallergics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Xiao-Feng Powder granules twice daily for 12 weeks plus Bilastine 20mg once daily for the first 6 weeks, and on-demand for the following 6 weeks.
Study: NCT04933617
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 750 mg/m\^2 intravenous (IV) on Day 5 of each cycle up to 6 cycles
Study: NCT04933617
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin 10 mg/m\^2/day continuous intravenous infusion (CIVI) on Days 1-4 of each cycle up to 6 cycles
Study: NCT06542614
Drug: TQH3906 capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: To assess the efficacy and safety of TQH3906 in subjects with moderate to severe plaque psoriasis.
Study: NCT06542614
Drug: Placebo of TQH3906 capsules
Normalized name: PLACEBO CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo without drug substance.
Study: NCT05014815
Drug: histology-based chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT05123599
Drug: ETV monohydrate
Normalized name: Lactose Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: ETV monohydrate film-coated tablets will be administered orally.
Study: NCT05123599
Drug: TAF
Normalized name: Altafed
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAF film-coated tablets will be administered orally.
Study: NCT04563026
Drug: DUR-928 30 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT04563026
Drug: Placebo+ Standard of Care (SOC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT05277571
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered iv or sc in Part A and iv in Part B to maintain the blinding.
Study: NCT04310865
Drug: Yinhu Qingwen Granula
Normalized name: Saxifraga granulata whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yinhu Qingwen Granula is a kind of herbal granula made from Yinhu Qingwen Decoction, which consits of 11 Chinese herbal medicine as Honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, etc. The granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml). It will be given a 200ml per time, three times a day, for 10 days.
Study: NCT04310865
Drug: Yin Hu Qing Wen Granula(low does)
Normalized name: Saxifraga granulata whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: This intervention is given as 10% dose of YinHu QingWen Granula.The granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml).
Study: NCT01049633
Drug: Antibacterial, Antifungal, and Antiviral Prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broad spectrum antimicrobial prophylaxis administered preoperatively
Study: NCT01049633
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 70U/kg body weight of recipient given with islet infusion, followed by 3U/kg/hr for the next 4hrs. From 5th through 48th hr post-transplant heparin will be titrated to achieve and maintain a Partial Thromboplastin Time (PTT) of 50-60 seconds. This medication is used to prevent the formation of blood clots.
Study: NCT05375708
Drug: Maintenance therapy (CAP-B or 5-FU/LV plus bevacizumab.)
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAP + bevacizumab (following CAPOX-B) Bevacizumab 7.5mg/kg i.v. on day 1 and 1250 mg/m2 of capecitabine, orally twice daily on days 1-14 if age is \<70 years and 1000 mg/m2 of capecitabine, orally twice daily on days 1-14 if age is higher than 70 years. CAP + bevacizumab is repeated every three weeks.~5-FU/LV + bevacizumab (following FOLFOX-B) Bevacizumab 5.0mg/kg i.v. together with leucovorin 400 mg/m2 i.v. bolus 5FU 400 mg/m2 all on day 1. Followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours. 5-FU + bevacizumab is repeated every two weeks.~5-FU/LV + bevacizumab (following FOLFOXIRI-B) Bevacizumab 5.0mg/kg i.v. together with leucovorin 400 mg/m2 i.v. all on day 1. Followed by continuous infusion of 5-fluorouracil 3200 mg/m2 in 46 hours. 5-FU + bevacizumab is repeated every two weeks.~When S1 is used a replacement for fluoropyrimidine therapy it is administered in a dose of 30mg/m2 twice daily on days 1-14. S1 is repeated every three weeks.
Study: NCT05374499
Drug: 0.5% bupivacaine with 1:100,000 epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage: 3 mL of diluted 0.5% bupivacaine with 1:200,000 epinephrine (2:1 ratio of saline to standard bupivacaine) Frequency: Administer via buccal infiltration technique immediately following mandibular third molar extraction surgery and at least twenty minutes following most recent lidocaine injection.
Study: NCT04683029
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered intravenously or subcutaneously.
Study: NCT06103721
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the placebo group will be nebulized with 10 ml of Normal Saline, 15 minutes prior to induction of general anesthesia. Then general anesthesia will be induced with 1mg of Midazolam, 2mg/kg of Propofol, 0.5 mg/kg of Atracurium. Prior to endotracheal tube placement, airway will be managed with bag mask ventilation for 3 minutes. Vitals will be measured pre-nebulization, pre-induction, at 1 minute intervals during bag mask ventilation and immediately after placement of endotracheal tube.
Study: NCT06005441
Drug: CBL-A2 Injection
Normalized name: PROCYANIDIN A2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provided as a ready for use injectable CBL-A2 solution
Study: NCT06719908
Drug: AFA-281 is a small molecule, orally available
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a study to evaluate the interaction of AFA-281 with alcohol
Study: NCT05045664
Drug: Experimental
Normalized name: WA-001 Experimental Soil Surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obinutuzumab with 2 x2 Gy involved site radiotherapy
Study: NCT05813145
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 patients will receive four cycle of AC followed by paclitaxel 80 mg/m2 weekly for 12 week
Study: NCT05178069
Drug: : Placebo for Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule manufactured without active ingredients.
Study: NCT05185089
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets to match orvepitant 30mg and 10mg tablets
Study: NCT05480553
Drug: NPC-06
Normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Initial dose (Day 1) \<Dose\> An 18 mg/kg of NPC-06 will be injected by intravenous drip infusion once daily. The maximum dose of the test drug should not exceed 1,200 mg as fosphenytoin sodium.~   \<Administration method\> Dilute the study drug 3 to 4-fold using physiological saline for intravenous infusion and then administer the solution over 18 minutes.~2. Maintenance dose(Day 2～7) Maintenance dose on the next day (Day 2) after the initial dose will be mandatory, and will be dosed up to 6 days. Maintenance dose on Day 3 and thereafter will follow the transition criteria for maintenance dose.~\<Dose\> A 7.5 mg/kg of NPC-06 will be injected as needed by intravenous drip infusion once daily. The maximum dose of NPC-06 should not exceed 500 mg as fosphenytoin sodium.~\<Administration method\> Dilute the study drug 3-to 4-fold using physiological saline for intravenous infusion and then administer the solution over 7 minutes and 30 seconds.
Study: NCT05480553
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Initial dose (Day 1) \<Dose\> A placebo will be injected by intravenous drip infusion once daily. \<Administration method\> Dilute the study drug 3 to 4-fold using physiological saline for intravenous infusion and then administer the solution over 18 minutes.~2. Maintenance dose(Day 2～7) Maintenance dose on the next day (Day 2) after the initial dose will be mandatory, and will be dosed up to 6 days. Maintenance dose on Day 3 and thereafter will follow the transition criteria for maintenance dose.~\<Dose\> A placebo will be injected as needed by intravenous drip infusion once daily. Dilute the study drug 3-to 4-fold using physiological saline for intravenous infusion and then administer the solution over 7 minutes and 30 seconds.
Study: NCT04417907
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy adults will take 2mg placebo PO QD for six weeks
Study: NCT04175392
Drug: Align Probiotic Supplement Capsule
Normalized name: Align Probiotic Supplement Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Align Probiotic 1 billion units, 1 capsule once daily
Study: NCT04175392
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebos capsule 1 capsule Once daily
Study: NCT06380764
Drug: Normal Saline 10 mL Injection
Normalized name: normal saline 10 mL Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drug
Study: NCT05297110
Drug: atherolive
Approvals — FDA: no, EMA: no, PMDA: no
Description: In each study population, the patient will be assigned to one of two treatments (atherolive or placebo) using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months. The placebo will be prescribed identically.
Study: NCT06211751
Drug: TQB3702 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB3702 is a kinase inhibitor.
Study: NCT06475326
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil: 2400mg/m2, Q2W
Study: NCT03834909
Drug: Standard dose Truvada®
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF/FTC fixed dose combination, 300 mg TDF/200 mg FTC, one tablet each day
Study: NCT03834909
Drug: Pregnancy-adjusted dose Truvada®
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF/FTC fixed dose combination, 300 mg TDF/200 mg FTC, two tablets each day
Study: NCT04843046
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules will be filled with corn starch and riboflavin.
Study: NCT04848259
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline will be applied after surgery
Study: NCT06577376
Drug: Simmitinib tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: A novel small molecule inhibitor targeting fibroblast growth factor receptor (FGFR), vascular endothelial growth factor receptor (VEGFR2, KDR), and colony-stimulating factor 1 receptor (CSF-1R)
Study: NCT05700656
Drug: Galunisertib plus capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Combination therapy with galunisertib plus capecitabine
Study: NCT04889820
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: After the surgery, adjuvant chemotherapy will be administered, and total perioperative chemotherapy will be administered with 12 cycles.